These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18335847)

  • 1. Ibuprofen and cardiovascular safety: where do we stand?
    Purcell H
    J R Soc Med; 2007; 100 Suppl 48():7-10. PubMed ID: 18335847
    [No Abstract]   [Full Text] [Related]  

  • 2. More pain for painkillers.
    Sifferlin A
    Time; 2013 Jun; 181(24):14. PubMed ID: 24044255
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
    Konstantinopoulos PA; Lehmann DF
    J Clin Pharmacol; 2005 Jul; 45(7):742-50. PubMed ID: 15951464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
    Prozzi GR; Cañás M; Urtasun MA; Buschiazzo HO; Dorati CM; Mordujovich-Buschiazzo P
    Medicina (B Aires); 2018; 78(5):349-355. PubMed ID: 30285927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
    Geis GS
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134853
    [No Abstract]   [Full Text] [Related]  

  • 8. NSAIDs and alcohol: never the twain shall mix?
    Pfau PR; Lichenstein GR
    Am J Gastroenterol; 1999 Nov; 94(11):3098-101. PubMed ID: 10566697
    [No Abstract]   [Full Text] [Related]  

  • 9. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance.
    Hohlfeld T; Saxena A; Schrör K
    Thromb Haemost; 2013 May; 109(5):825-33. PubMed ID: 23238666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
    Lanza FL; Rack MF; Simon TJ; Quan H; Bolognese JA; Hoover ME; Wilson FR; Harper SE
    Aliment Pharmacol Ther; 1999 Jun; 13(6):761-7. PubMed ID: 10383505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin and cyclooxygenase-2 inhibitors.
    Armstrong TA
    Am J Health Syst Pharm; 2003 Jul; 60(14):1481. PubMed ID: 12892035
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
    Laine L; Maller ES; Yu C; Quan H; Simon T
    Gastroenterology; 2004 Aug; 127(2):395-402. PubMed ID: 15300570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New reports on dental analgesics. NSAIDs and cardiovascular effects, celecoxib for dental pain, and a new analgesic--tramadol with acetaminophen.
    Wynn RL
    Gen Dent; 2002; 50(3):218-20, 22. PubMed ID: 12116507
    [No Abstract]   [Full Text] [Related]  

  • 15. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Umar A; Boisseau M; Yusup A; Upur H; Bégaud B; Moore N
    Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 inhibitors and cardiovascular risk.
    Flattery MP; Hylton Gravatt LA
    Prog Cardiovasc Nurs; 2005; 20(3):123-5. PubMed ID: 16030414
    [No Abstract]   [Full Text] [Related]  

  • 17. [Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?].
    Flipo RM
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S53-60. PubMed ID: 17078596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insights and views about cardiovascular safety of COX2 inhibitors].
    Wallentin L
    Lakartidningen; 2005 Feb 28-Mar 6; 102(9):666, 668, 671. PubMed ID: 15804041
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibuprofen and asthma in paediatric populations: clinical concern or clinical reality?
    Kanabar D
    J R Soc Med; 2007; 100 Suppl 48():15-7. PubMed ID: 18335849
    [No Abstract]   [Full Text] [Related]  

  • 20. [Are COX-2 inhibitors a risk factor for cardiovascular disease?].
    John S; Schmieder RE
    Dtsch Med Wochenschr; 2002 Jan; 127(4):156-9. PubMed ID: 11807660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.